G1 Therapeutics Announces Positive Myelopreservation Data

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data from its randomized, double-blind, placebo-controlled Phase 2 trial evaluating...

Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death

Genentech, a member of the Roche Group (SIX:RO,ROG;OTCQX:RHHBY) announced results from the Phase III IMpower132 study of TECENTRIQ (atezolizumab) plus pemetrexed...

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy

Pieris Pharmaceuticals (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced...